Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the ...
Ocular Therapeutix is reprioritizing its regulatory strategy for Axpaxli, aiming for a quick approval based on the SOL-1 trial's one-year data. OCUL’s recent rally reflects optimism around a faster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results